Genentech : FDA Approves Susvimo For Diabetic Macular Edema Treatment
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...
Business Wire1d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
ophthalmologytimes1d
FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Roche's Susvimo gets FDA approval for diabetic macular edema
Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...
verywellhealth5d
New FDA-Approved Painkiller Is a Safer Alternative to Opioids
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.